3‑Bromopiperidine‑2,6‑dione (3‑bromo‑2,6‑piperidinedione, CAS: 62595‑74‑8) is a halogenated glutarimide derivative with the molecular formula C₅H₆BrNO₂ and a molecular weight of 192.01 g/mol. Structurally, it consists of a piperidine‑2,6‑dione core bearing a bromine substituent at the 3‑position. This compact bicyclic motif — the 3‑substituted glutarimide scaffold — provides an ideal platform for constructing immunomodulatory drugs and cereblon‑based protein degraders. The reactive bromine atom at the 3‑position is optimally sized and polarized to undergo efficient nucleophilic aromatic substitution and cross‑coupling reactions, enabling the rapid construction of diverse glutarimide libraries while minimizing undesirable side reactions.
Glutarimide derivatives represent one of the most commercially and clinically significant classes of small‑molecule therapeutics. As a key upstream building block, 3‑bromopiperidine‑2,6‑dione is the preferred electrophilic intermediate for constructing immunomodulatory drugs (IMiDs) — the core of the billion‑dollar oncology and immunology drug market. Unlike its 3‑chloro, 3‑iodo, or 3‑amino counterparts, the bromine atom‘s optimal size and polarizability ensure superior nucleophilic substitution kinetics while maximizing coupling efficiency, making it the electrophilic reagent of choice for assembling the glutarimide ring system found in therapeutic IMiDs.
Core Application Fields
1. IMiD Immunomodulatory Drug Synthesis — The Primary Demand Driver (≈70‑80 % of total consumption)
3‑Bromopiperidine‑2,6‑dione serves as the direct synthetic precursor to the entire class of IMiD therapeutics, which includes three blockbuster drugs: thalidomide, lenalidomide (Revlimid®), and pomalidomide (Pomalyst®). Lenalidomide alone achieved peak annual sales exceeding USD 12 billion, with the global IMiD market projected to maintain a CAGR of 5‑7 % through 2030, driven by expanding indications in multiple myeloma, myelodysplastic syndromes, and various hematologic malignancies.
The standard industrial synthesis of lenalidomide employs 3‑bromopiperidine‑2,6‑dione as a key electrophilic intermediate: bromination of glutarimide with bromine in acetic acid produces 3‑bromopiperidine‑2,6‑dione, which is then condensed with 4‑nitro‑2,3‑dihydroisoindol‑1‑one in DMF with potassium carbonate to yield the nitro precursor, ultimately leading to lenalidomide following reduction. This robust, multi‑step sequence is scalable from research grams to industrial metric tons.
2. Cereblon‑Based PROTAC Synthesis — The Fastest Growing Segment (≈15‑20 % of total consumption)
Cereblon is a substrate receptor for the CUL4‑RBX1‑DDB1‑CRBN E3 ubiquitin ligase complex. IMiDs function as molecular glues that bind cereblon and alter its substrate specificity, leading to the targeted degradation of neo‑substrates. In PROTAC (proteolysis‑targeting chimera) design, the glutarimide core — directly derived from 3‑bromopiperidine‑2,6‑dione — serves as the cereblon‑binding warhead that recruits the E3 ligase machinery to a target protein of interest. Through the reactive bromine handle, 3‑bromopiperidine‑2,6‑dione allows rapid diversification of the glutarimide scaffold via nucleophilic substitution with various linkers, enabling the construction of heterobifunctional PROTAC molecules with high selectivity and degradation efficiency. The global PROTAC market was valued at approximately USD 1.2 billion in 2024 and is projected to reach USD 6.2 billion by 2030, exhibiting an extraordinary CAGR of 31 %.
3. Synthesis of Thalidomide Analogues and SAR Exploration
Beyond lenalidomide and pomalidomide, 3‑bromopiperidine‑2,6‑dione is employed as the versatile starting material for generating libraries of novel glutarimide derivatives in structure‑activity relationship (SAR) campaigns. The compound reacts with sodium saccharin to synthesize glutarimide derivatives that have demonstrated activity against Ehrlich ascites carcinoma in Swiss albino mice. It is also used in the preparation of glutarimide derivatives showing potential activity in sickle cell disease and β‑thalassemia research via induction of fetal hemoglobin expression. The versatility of the bromine leaving group enables rapid exploration of the glutarimide scaffold‘s chemical space, accelerating lead optimization across multiple therapeutic areas.
4. Anticancer and Neurological Disorder Therapeutics
3‑Bromopiperidine‑2,6‑dione serves as a key building block for anticancer drug candidates and intermediates in neurological disorder therapeutics. Glutarimide derivatives synthesized from this scaffold have shown promise as enzyme inhibitors and as agents targeting pathways relevant to Parkinson‘s disease and other CNS disorders.
5. Agrochemical Building Block
In the crop protection sector, 3‑bromopiperidine‑2,6‑dione is used as a building block in the synthesis of agrochemicals, including insecticides, herbicides, and fungicides, as well as plant growth regulators that enhance crop yield and development.
Major Market Participants
The global supply system for 3‑bromopiperidine‑2,6‑dione follows a pattern of specialized fine chemical and pharmaceutical intermediate manufacturers, with China and India dominating large‑scale production, and Japan, Europe, and North America serving high‑purity R&D and GMP‑grade manufacturing.
Leading international suppliers include TCI Chemicals (purity >98 %), BOC Sciences, AK Scientific, BenchChem, MuseChem, LeapChem, and Ningbo Inno Pharmchem Co., Ltd. The compound is generally supplied as a white to light‑yellow crystalline solid with purity ranging from 95 % to ≥98 % (GC), melting point 107‑111 °C, and recommended storage at 2‑8 °C under inert atmosphere.
Shanghai XinChem Co., Ltd. has established a reliable, fully quality‑controlled supply chain for high‑purity 3‑bromopiperidine‑2,6‑dione (CAS 62595‑74‑8). Our product meets rigorous pharmaceutical intermediate specifications — purity ≥98 % (GC), white to light‑yellow crystalline solid, molecular weight 192.01 g/mol, MDL MFCD11053059, controlled residual solvents (<0.5 % total), and heavy metals (≤10 ppm, ICH Q3D compliant) — fully compliant with global IMiD API and PROTAC synthesis standards. XinChem is well‑positioned to serve the rapidly growing global demand from IMiD API manufacturers, PROTAC developers, CROs/CDMOs, and academic research institutions.
Regional Market Dynamics
Asia‑Pacific is the largest and fastest‑growing region for 3‑bromopiperidine‑2,6‑dione production. China has emerged as the dominant manufacturing hub for pharmaceutical glutarimide intermediates, producing high‑purity material at highly competitive prices, while India‘s rapidly growing generic IMiD sector drives significant volume demand. North America and Europe command the largest share of high‑purity R&D consumption, with stringent quality requirements (≥99 % purity, full enantiomeric documentation, ICH Q3D compliance) and the highest concentration of PROTAC development programs. Japan and South Korea demand ultra‑high‑purity grades for advanced API development and heterobifunctional degrader synthesis.
Regulatory and Environmental Considerations
3‑Bromopiperidine‑2,6‑dione (CAS 62595‑74‑8) is classified as a non‑hazardous material for transport (not classified as dangerous goods for shipping, ADR 2.2). Storage conditions: 2‑8 °C in a tightly sealed container, protected from light, moisture, strong oxidizing agents, and strong acids, stored under inert gas (nitrogen or argon) due to air sensitivity. Recommended long‑term storage: 2‑8 °C, sealed, dry, light‑protected. In the European Union, the compound is subject to REACH regulations; importers and manufacturers must provide Safety Data Sheets (SDS). In the United States, it is regulated under TSCA as a research chemical; for pharmaceutical API use, adherence to cGMP guidelines (21 CFR Parts 210/211) is required. In China, the compound is listed in the Inventory of Existing Chemical Substances (IECSC) and requires safety production licenses for manufacturing facilities.
Future Outlook
The market outlook for 3‑bromopiperidine‑2,6‑dione is tied to four core drivers: (1) the continued expansion of the global IMiD drug market, with lenalidomide generic competition and new IMiD derivatives entering clinical pipelines; (2) the explosive growth of the PROTAC field, where glutarimide‑based cereblon binders are the dominant E3 ligase recruiting warhead; (3) the rapid growth of Asian CRO/CDMO sectors supplying intermediates to global pharmaceutical companies; and (4) the increasing demand for glutarimide derivatives in oncology, immunology, CNS drug discovery, and crop protection. Enterprises should focus on securing high‑purity (≥98 %, >99 % for PROTAC applications) production capabilities, maintaining rigorous impurity documentation for pharmaceutical regulatory filings, and building long‑term supply partnerships with IMiD API manufacturers, PROTAC biotechs, CROs, and research institutions.
Shanghai XinChem Co., Ltd. (XinChem)
As a world‑leading supplier of pharmaceutical intermediates and heterocyclic building blocks, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the IMiD API manufacturing, PROTAC drug discovery, and oncology intermediate industries. Relying on core advantages in heterocyclic bromination, purification, and quality assurance, we provide high‑quality 3‑Bromopiperidine‑2,6‑dione (CAS 62595‑74‑8) to global customers.
1. Technical Advantages
- High Purity & Consistency: Our product achieves purity ≥98 % (GC), white to light‑yellow crystalline solid, molecular weight 192.01 g/mol, melting point 107‑111 °C, MDL MFCD11053059, and moisture <0.5 % (KF titration).
- Low Impurity Profile: Strict control of residual solvents (<0.5 % total), heavy metals (≤10 ppm, ICH Q3D compliant), and related substances by GC‑FID/HPLC‑UV ensures high synthetic performance for IMiD API manufacturing and PROTAC linker conjugation.
- Batch‑to‑Batch Uniformity: Rigorous analytical testing (GC, HPLC, NMR, LC‑MS, heavy metals by ICP‑MS, residual solvents by GC‑headspace) guarantees consistent quality and reproducible yields across all production lots.
2. Product Advantages
- Preferred IMiD Intermediate: The optimal bromine leaving group provides superior nucleophilic substitution kinetics for constructing lenalidomide, pomalidomide, and other glutarimide‑based drug candidates.
- Cereblon‑Binding Warhead for PROTACs: Directly used as the E3 ligase recruiting motif for heterobifunctional PROTAC synthesis; enables rapid diversification of the glutarimide scaffold via nucleophilic substitution with various chemical linkers.
- Scalable Multi‑Kilogram Synthesis: Validated for research grams (1 g, 5 g, 10 g, 25 g, 50 g, 100 g, 500 g) and bulk industrial production (1 kg, 5 kg, 10 kg, 25 kg). Full custom packaging available for IMiD campaigns.
- Flexible Packaging Options: 1 g, 5 g, 10 g, 25 g, 50 g, 100 g, 500 g glass bottles (R&D); 1 kg HDPE containers (pilot); 5 kg, 10 kg, 25 kg fiber drums (industrial). Full custom packaging available.
- Reliable Supply Chain: Annual capacity in the multi‑ton range, with dedicated temperature‑controlled warehousing (2‑8 °C, under inert gas, dry, light‑protected, sealed containers) and just‑in‑time delivery.
3. Application Fields
- Pharmaceutical Intermediates: Key building block for lenalidomide (Revlimid®), pomalidomide (Pomalyst®), thalidomide, and next‑generation IMiD drug candidates; glutarimide‑based cereblon binders for PROTAC synthesis.
- Cereblon‑Based PROTAC Synthesis: E3 ligase recruiting warhead for heterobifunctional protein degraders targeting oncology, immunology, inflammation, and CNS disorders.
- Anticancer & Neurological APIs: Building block for glutarimide derivatives with activity against multiple myeloma, myelodysplastic syndromes, lymphoma, and CNS disorder pathways.
- Agrochemical Intermediates: Building block for insecticides, herbicides, fungicides, and plant growth regulators.
- SAR Library Construction: Versatile electrophile for generating diverse glutarimide libraries for hit‑to‑lead optimization and drug discovery campaigns.
4. Service Support
Our technical team provides full impurity profiling (GC purity, residual solvents by GC‑headspace, heavy metals by ICP‑MS, LC‑MS identity confirmation), custom purification to any desired specification, and complete regulatory documentation (Certificate of Analysis, Technical Data Sheet, Safety Data Sheet, REACH compliance, TSCA certification, DMF support for pharmaceutical customers). We also offer custom synthesis of glutarimide derivatives, cold‑chain logistics, and just‑in‑time delivery.
5. Why Choose XinChem
- Professionalism: 20 + years in the pharmaceutical intermediate and heterocyclic bromination industry.
- Flexibility: Tailored to customer purity specifications, packaging sizes, and regulatory documentation requirements.
- Cost‑effectiveness: High purity at competitive industrial pricing.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Jun-01-2026